Tag archives : COVID-19 Pandemic

  Patients with haemoglobin disorders, particularly β-thalassaemia or sickle cell disease (SCD) or combined forms, on account of their underlying disease pathology and associated (iron load mainly in the case of thalassaemia) co-morbidities, are defined as high-risk individuals, prone to develop more severe complications from SARS-COV-2. Despite the fact that ...

    9 patients with thalassaemia, members of TIF’s Patient Advocacy Group for Thalassaemia and Sickle Cell Disease (T-PAG), are discussing with the Thalassaemia International Federation the accessibility and affordability of the new and innovative Therapies for the disease, as well as the COVID-19 pandemic challenges in their respective countries. ...

As the online celebrations for the International Thalassaemia Day 2020 are at their peak, TIF decided to publish today as a gift to its worldwide patient communities a new guide entitled  »COVID-19 & Haemoglobin Disorders: A Classification of Risk Groups & Other Considerations ». Patients with thalassaemia and sickle cell disease ...

A TIF-compiled document aiming to provide a division of risk levels for thalassaemia and SCD patients with regards to the ongoing COVID-19 pandemic.

All the latest updates of TIF’s Vaccinations & Therapeutic Drugs Guide for COVID-19 gathered in one single document.

  Given the unprecedented global public health crisis brought on by the COVID-19 pandemic, TIF announces that the celebrations of the International Thalassaemia Day 2020 on the 8th of May, including all the Federation’s activities that were initially programmed, are rescheduled for Monday, 8 September 2020. TIF strongly urges its members ...

An unprecedented collaboration across government, academia, private sector, and philanthropy is taking place as a response to the coronavirus global crisis. Today, a consortium of life sciences companies announced an important collaboration to accelerate the development, manufacture, and delivery of vaccines, diagnostics, and treatments for COVID-19. The life sciences industry ...

  Global regulators have published a report today presenting the outcomes of a workshop on COVID-19 vaccine development that was convened under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA). This report was the outcome of March 18th first global regulators meeting, chaired jointly by the the ...